Filing Flows › Comparisons › HALO vs TECH
Halozyme Therapeutics vs Bio-Techne: HALO and TECH compared
Halozyme Therapeutics is the larger company: $493M of revenue in its latest quarter (Q3 2026) against $300M for Bio-Techne (Q1 FY27). Halozyme Therapeutics is growing faster (+39% against +5% a year earlier). Halozyme Therapeutics is more profitable, with an operating margin of 59.8% against 12.2%.
Where the money goes: HALO and TECH
Halozyme Therapeutics (HALO) · Q3 2026
Halozyme Therapeutics, Q3 2026: revenue $493M (+39% year over year), operating margin 59.8%, net earnings $247M, operating cash flow $258M. The chart follows the revenue to costs, profit and cash.
Bio-Techne (TECH) · Q1 FY27
Bio-Techne, Q1 FY27: revenue $300M (+5% year over year), operating margin 12.2%, net earnings $28.3M, operating cash flow $73.1M. The chart follows the revenue to costs, profit and cash.
| Halozyme Therapeutics (HALO) | Bio-Techne (TECH) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q1 FY27 |
| Revenue | $493M | $300M |
| Revenue growth, Y/Y | +39% | +5% |
| Gross margin | — | 65.6% |
| Operating margin | 59.8% | 12.2% |
| Net earnings | $247M | $28.3M |
| Net margin | 50.1% | 9.4% |
| Operating cash flow | $258M | $73.1M |
| Free cash flow | $255M | $67.2M |
| Market value | $12.7B | $11.4B |
| P/E | 26.2× | 62.9× |
| Analysts’ mean target | $109.67 | $70.50 |
Where the revenue comes from
Halozyme Therapeutics
- Royalties: $341M (69%)
- Product sales, net: $137M (28%)
- Revenues under collaborative agreements: $14.6M (3%)
Bio-Techne
- Product and Services: $285M (95%)
- Royalty: $14.5M (5%)
Questions
Which is bigger, Halozyme Therapeutics or Bio-Techne?
Halozyme Therapeutics is the larger company: $493M of revenue in its latest quarter (Q3 2026) against $300M for Bio-Techne (Q1 FY27).
Is Halozyme Therapeutics or Bio-Techne growing faster?
Halozyme Therapeutics is growing faster (+39% against +5% a year earlier).
Which is more profitable, Halozyme Therapeutics or Bio-Techne?
Halozyme Therapeutics is more profitable, with an operating margin of 59.8% against 12.2%.
More: Halozyme Therapeutics earnings · how Halozyme Therapeutics makes money · Bio-Techne earnings · how Bio-Techne makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 5, 2026; 10-Q filed Nov 6, 2026). Fiscal quarters can end on different dates. Not investment advice.